Business Wire

Reduced Data Accuracy Helps Save Energy – Tampere University, Finland, Is Coordinating a Project That Trains Young Scientists From Around the World to Develop Solutions

Share

It is estimated that by 2040, computers will need more electricity than the world’s energy resources can generate. The Approximate Computing for Power and Energy Optimisation (APROPOS) project will train 15 junior researchers around Europe to tackle the challenges of future-embedded and high-performance computing energy efficiency by using disruptive methodologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005657/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Professor Jari Nurmi is coordinating the APROPOS project and co-supervising four of its researchers. His current research interests include approximate and reconfigurable computing, software-defined radio and networks, and wireless positioning hardware. Photo: Sari Laapotti

The energy consumption of mobile broadband networks is comparable to that of data centres. The Internet of Things paradigm will soon connect up to 50 billion devices through wireless networks. The APROPOS project aims at decreasing energy consumption in both distributed computing and communications for cloud-based cyber-physical systems.

“Luckily, in many parts of global data acquisition, transfer, computation, and storage systems, it’s possible to reduce accuracy to allow reduced energy and time consumption. By introducing accuracy to design optimisation, energy efficiency can be improved even up to 50-fold,” says Professor Jari Nurmi from the Electrical Engineering Unit of Tampere University.

Nurmi points out that, for example, numerous sensors measure noisy or inexact inputs, and the algorithms processing the acquired signals can be stochastic. Sensor swarms measuring natural environments produce a lot of noisy and inexact data that can be transferred and processed with less accuracy without losing the essential trends of the phenomena observed.

”The applications using data may not need completely correct results; acceptable accuracy may be sufficient. This means that the system can be resilient against random errors and, for example, a coarse classification may be enough for a data mining system.”

New solutions needed to tackle increasing energy consumption

The overall energy consumption of computing and communication systems is rapidly growing, despite the recent advances in semiconductor technology and energy-aware system design. The APROPOS project will train fifteen research fellows in a multisectoral, international environment to form the basis for enhanced features in products and energy-aware system design.

“The early-stage researchers of APROPOS will be trained in both entrepreneurial and academic directions. Thus, they will be able to develop the commercial potential of their research and come up with innovative product and service ideas,” Nurmi adds.

APROPOS is a four-year project funded by the European Union’s Horizon 2020 Marie Sklodowska Curie Innovative Training Networks. It is coordinated by Tampere University, Finland. Many of the young researchers are coming from outside the EU to work in Finland, Sweden, the Netherlands, Austria, Italy, Spain, Switzerland, France, and the UK.

Read more at http://www.apropos-itn.eu

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Professor Jari Nurmi, Tampere University
tel. +358 40 506 4460
jari.nurmi@tuni.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye